All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
This month, the National Institute for Health and Care Excellence (NICE) has released guidance on using AbbVie/Roche’s Venclyxto® (venetoclax) in the NHS in England, stating that they reject Venclyxto® for the treatment of CLL patients who have del(17p) or TP53 mutation and are unsuitable for, or progressed after, BCR pathway inhibitor treatment or whose disease progressed after both chemoimmunotherapy and a BCR pathway inhibitor.
The main reason for this rejection is that too many doubts and reservations were raised with venetoclax’s clinical evidence base, and so it not a cost-effective use of NHS resources.
The cost of the agent has also been a hurdle for NICE approval; 28 days of 400mg treatment (112-pack of 100mg tablets) costs £4,789.47 plus VAT.
Moreover, NICE made the decision that venetoclax should not be reimbursed by the new Cancer Drugs Fund (this makes drugs available for a short time so more conclusive clinical data and evidence can be collected).
NICE state that “This guidance is not intended to affect the position of patients whose treatment with venetoclax was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.”
On 8th December 2016, the European Medicines Agency (EMA) granted Venclyxto® monotherapy conditional marketing authorization for the specific CLL indications mentioned above, and so is available in European countries. This decision was based on phase 2 data; but as it is conditional, the marketing authorization will be reviewed annually until late-stage data can be provided. Moreover, in April 2016, the US Food and Drug Administration (FDA) approved venetoclax, marketed as Venclexta®, for CLL patients the del(17p) and who have received at least one previous treatment.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox